Development of ther apeutic method based on molecular biological characteristics in lung cancer cells.
| Project/Area Number |
14570545
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | TOYAMA MEDICAL AND PHARMACEUTICAL UNIVERSITY |
|---|
Principal Investigator |
KASHII Tatsuhiko Toyama Medical and Pharmaceutical University, Hospital, Instructor, 附属病院, 助手 (00313619)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2003: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2002: ¥2,500,000 (Direct Cost: ¥2,500,000)
|
|---|
| Keywords | gefitinib / EGFR / NSCLC / FDG-PET / chemotherapy / lung / cancer / molecular target agents / FDG-PET / ZD-1839 |
|---|
| Research Abstract |
In this study, we investigated effect and mechanism of cytotoxic anti-cancer agents and EGFR-TKI in non-small cell lung cancer and biological analysis using FDG-PET for the patients treated with gefitinib as follows.
1)In vitro study : Combination effects of EGF-TKI, gefitinib, tamoxifen and cytotoxic agents were observed in vitro. Additional effect of gefitinib and tamoxifen was observed in high concentration of estradiol.
2)FDG-PET study : Fluorine-18 fluorodeoxyglucose positron emission tomography(FDG-PET) scan is reported as useful and accurate nuclear medicine method for diagnosis of malignancy/benign. staging, metastasis and recurrence in primary lung cancer. Gefitinib(IRESSA ○!R ) is an orally active, selective EGFR-tyrosine kinase inhibitor that blocks signal transduction pathways implicated in proliferation and survival of cancer cells. Phase II trial to evaluate objective tumor response rate and safety of ZD1839 was operated worldwide in patients with previously treated NSCLC. In this study, we aimed to evaluate-the usefulness of FDG-PET scan for the response of gefitinib in NSCLC. Fourteen patients of recurrent or chemotherapy refractory NCSLC administered 250mg/day of gefitinib were analyzed. Twelve patients treated with gefitinib evaluated the response using conventional CT scan were compared with FDG-PET scan at a time. Four PRs. 8 SDs and 2 PD were evaluated with CT scan. Eight of 12(66.7%) patients had the same result with both methods. Four SDs(33.3%) evaluated with CT scan had a result of PR in FDG-PET scan. Two of these patients were reevaluated to PR with CT scan in 4-8 weeks later. Conclusions : These results suggest that the response of FDG-PET scan was earlier than that of CT scan in patients treated with gefitinib. FDG-PET scan might be used in routine practice to evaluate the chemotherapeutic response of molecular target agents including gefitinib in primary lung cancer.
|
Report
(3 results)
Research Products
(3 results)
